These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 4440586)
1. The "on-off" side effect of L-DOPA. Markham CH Adv Neurol; 1974; 5():387-96. PubMed ID: 4440586 [No Abstract] [Full Text] [Related]
2. The "on-off" response to chronic L-DOPA treatment of Parkinsonism. Sweet RD; McDowell FH Adv Neurol; 1974; 5():331-8. PubMed ID: 4440581 [No Abstract] [Full Text] [Related]
3. Variations in the "on-off" phenomenon. Duvoisin RC Adv Neurol; 1974; 5():339-40. PubMed ID: 4440582 [No Abstract] [Full Text] [Related]
4. Short- and long-term approaches to the "on-off" phenomenon. Papavasiliou PS; Cotzias GC; Mena I Adv Neurol; 1974; 5():379-86. PubMed ID: 4440585 [No Abstract] [Full Text] [Related]
5. Dihydroxyphenylacetic acid in the treatment of Parkinsonism. Ericsson AD; McCann DS Adv Neurol; 1974; 5():301-6. PubMed ID: 4440578 [No Abstract] [Full Text] [Related]
6. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)]. Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081 [No Abstract] [Full Text] [Related]
7. Parkinson's disease; modern treatment. Tolosa E Minn Med; 1973 Jun; 56(6):497-502. PubMed ID: 4575903 [No Abstract] [Full Text] [Related]
8. Haloperidol in dopa-induced choreo-athetosis. Postma JU Psychiatr Neurol Neurochir; 1972; 75(1):69-71. PubMed ID: 5024898 [No Abstract] [Full Text] [Related]
9. "On-off" syndrome treated with lithium carbonate: a case report. Ross DR; Coffey CE; Ferren EL; Walker JI; Olanow CW Am J Psychiatry; 1981 Dec; 138(12):1626-7. PubMed ID: 6795945 [TBL] [Abstract][Full Text] [Related]
10. The "on-off" effect. Carlsson A Adv Neurol; 1974; 5():367-8. PubMed ID: 4155235 [No Abstract] [Full Text] [Related]
11. [Results after 3 to 5 years of treatment of 219 cases of Parkinson's syndrome treated by L-Dopa and an L-Dopa -decarboxylase inhibitor combination]. Boudin G; Pepin B; Guillard A; Godlewski S; Fabiani JM; Haguenau M Rev Neurol (Paris); 1974; 130(7-8):273-84. PubMed ID: 4217929 [No Abstract] [Full Text] [Related]
12. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients]. Hironishi M; Miwa H; Kondo T No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758 [TBL] [Abstract][Full Text] [Related]